A major international Phase III clinical trial, led by Queen Mary University of London, has found that ocrelizumab—a ...
SAN DIEGO — Results from two phase 3 trials offer mixed findings on the potential of experimental Bruton tyrosine kinase (BTK) inhibitors for primary progressive multiple sclerosis (PPMS). Findings ...
Higher-dose ocrelizumab produced greater peripheral B-cell depletion than the approved 600 mg regimen in two phase 3b trials ...
In people with primary progressive multiple sclerosis (PPMS), depressive symptoms measured using the Hospital Anxiety and Depression Scale (HADS) predicted subsequent neurologic disability progression ...
A major international phase III clinical trial, led by Queen Mary University of London, has found that ocrelizumab – a ...
CHARLESTON, S.C. (WCSC) - Hundreds of people gathered at James Island County Park to participate in a Walk MS event, fundraising for research and raising awareness about the autoimmune disease ...
The US Food and Drug Administration (FDA) is reviewing a petition to revoke the approval of Roche's top-selling drug ocrelizumab (Ocrevus) for treating primary progressive multiple sclerosis (PPMS)—a ...
– Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the current standard of care, Ocrevus, in ...
The International Progressive MS Alliance has awarded €6.9 million to three global studies aimed at finding solutions for the most common symptoms experienced by people living with progressive MS, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results